优化溃疡性结肠炎患者英夫利西单抗诱导期给药方案
该研究基于204例溃疡性结肠炎患者的583个样本建立群体药动学模型,并利用159例患者构建暴露-反应模型,发现累积药时曲线下面积(CAUCendoscopy)是预测黏膜愈合的最佳暴露指标,模型预测第0、14、42天给药且第84天CAUCendoscopy目标为3752 mg/L*day时,70%患者可达黏膜愈合。
要点
- CAUCendoscopy是预测英夫利西单抗诱导期黏膜愈合的最佳暴露指标。
- 群体药动学模型显示C反应蛋白、白蛋白、基线MES、去脂体重、合并糖皮质激素和全结肠炎影响暴露。
- 基于TDM的剂量个体化 targeting CAUCendoscopy 有望改善诱导期疗效。
核心结论
- 基于TDM的剂量个体化,以CAUCendoscopy为目标,有可能提高英夫利西单抗诱导期治疗的疗效。
研究设计与样本
- 回顾性研究,从临床数据库收集204例患者的583个样本用于建立群体药动学模型,其中159例患者用于构建逻辑回归暴露-反应模型。
主要发现
- 一室群体药动学模型(含个体间和个体内变异)拟合数据最佳。
- 影响暴露的协变量包括C反应蛋白、白蛋白、基线MES、去脂体重、合并使用糖皮质激素和全结肠炎。
- CAUCendoscopy是预测黏膜愈合(基线MES>1且诱导后MES≤1)的最佳暴露指标。
- 模型预测,在第0、14、42天给予英夫利西单抗,且第84天CAUCendoscopy目标为3752 mg/L*day时,70%的患者将达到黏膜愈合。
关键数值与推荐
- 模型预测的CAUCendoscopy目标值为3752 mg/L*day(第84天),给药方案为第0、14、42天。
临床怎么用
- 临床可基于TDM个体化调整英夫利西单抗诱导期剂量,以CAUCendoscopy为目标优化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The therapeutic failure of infliximab therapy in patients with ulcerative colitis remains a challenge even 2 decades after its approval. Therapeutic drug monitoring (TDM) has shown value during maintenance therapy, but induction therapy has still not been explored. Patients may be primary nonresponders or underexposed with the standard dosing regimen. We aimed to: (i) develop a population pharmacokinetic-pharmacodynamic model; (ii) identify the best exposure metric that predicts mucosal healing; and (iii) build an exposure-response (ER) model to demonstrate model-based dose finding during induction therapy with infliximab. METHODS: Data were retrospectively collected from a clinical database. A total of 583 samples, from 204 patients, was used to develop a population pharmacokinetic model to generate exposure metrics for subsequent ER modelling. A subset of 159 patients was used to develop a logistic regression ER model, describing the relationship between infliximab exposure and ordered transitions between Mayo endoscopic subscore (MES) 3, 2 and ≤1 (baseline to post-induction). RESULTS: A 1-compartment population pharmacokinetic model with interindividual and interoccasion variability was found to fit the data best. Covariates influencing exposure were C-reactive protein, albumin, baseline MES, fat-free mass, concomitant corticosteroid use and pancolitis. The cumulative area under the infliximab concentration-time curve until endoscopy (CAUCendoscopy ) was found to be the best exposure metric for predicting mucosal healing (baseline MES >1 and post-induction MES ≤1). The model predicted that 70% of patients will attain mucosal healing with infliximab administered at days 0, 14 and 42 and a target CAUCendoscopy of 3752 mg/L*day at day 84. CONCLUSIONS: TDM-based dose individualisation targeting CAUCendoscopy has the potential to improve the effectiveness of infliximab during induction therapy.
引用
- Dreesen E, Faelens R, Van Assche G, et al. Optimising infliximab induction dosing for patients with ulcerative colitis. Br J Clin Pharmacol. 2019. PMID: 30634202. doi:10.1111/bcp.13859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。